Ginkgo Bioworks Files 8-K: Other Events Reported

TL;DR

Ginkgo Bioworks filed an 8-K for 'Other Events' on 8/29/25 - details TBD.

AI Summary

Ginkgo Bioworks Holdings, Inc. filed an 8-K on August 29, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself. The company, formerly known as Soaring Eagle Acquisition Corp. and Spinning Eagle Acquisition Corp., is incorporated in Delaware and headquartered in Boston, MA.

Why It Matters

This filing indicates that Ginkgo Bioworks has reported significant events to the SEC, but the lack of detail requires further investigation to understand the implications for the company.

Risk Assessment

Risk Level: medium — The filing is an 8-K for 'Other Events' without specific details, which could indicate significant but undisclosed developments.

Key Players & Entities

• Ginkgo Bioworks Holdings, Inc. (company) — Registrant
• Soaring Eagle Acquisition Corp. (company) — Former Company Name
• Spinning Eagle Acquisition Corp. (company) — Former Company Name
• August 29, 2025 (date) — Filing Date and Earliest Event Date
• Delaware (jurisdiction) — State of Incorporation
• Boston, MA (location) — Principal Business Address

FAQ

Key Financial Figures

• $0.0001 — stered Class A common stock, par value $0.0001 per share DNA NYSE Indicate by check
• $4,125,000 — eceive a payment funded by insurance of $4,125,000, out of which amount plaintiffs' counse
• $2,750,000 — will request a fee and expense award of $2,750,000; (ii) the Company will adopt and mainta

Filing Documents

• dna-20250829.htm (8-K) — 24KB
• 0001628280-25-041399.txt ( ) — 140KB
• dna-20250829.xsd (EX-101.SCH) — 2KB
• dna-20250829_lab.xml (EX-101.LAB) — 22KB
• dna-20250829_pre.xml (EX-101.PRE) — 13KB
• dna-20250829_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events. On May 27, 2025, Ginkgo Bioworks Holdings, Inc. (the "Company") entered into a Stipulation and Agreement of Settlement (the "Stipulation of Settlement") to resolve certain stockholder derivative actions commenced nominally on behalf of the Company against certain individual defendants entitled: (i) Hu v. Baker et al., Case No. 4:23-cv-02077-KAW (N.D. Cal.); (ii) Bowers v. Kelly et al., 4:23-cv-05396-KAW (N.D. Cal.); and (iii) In re Ginkgo Bioworks Holdings, Inc. Stockholder Derivative Litigation, C.A. No. 2024-0361-KSJM (Del. Ch.) (collectively, the "Derivative Actions"). The Stipulation of Settlement is subject to the approval of the United States District Court for the Northern District of California (the "Court"). On August 21, 2025, the Court issued an order granting preliminary approval of the Stipulation of Settlement, requiring the Company to issue notice to stockholders, and setting a final hearing for December 18, 2025 at 1:30 p.m. PST. For additional information about the proposed settlement, stockholders may review the Stipulation of Settlement (with all exhibits thereto) and a Notice of Pendency of Proposed Settlement of Derivative Actions at https://investors.ginkgobioworks.com/overview/default.aspx. The foregoing summary description of the Stipulation of Settlement is qualified in its entirety by the full text of such documents.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GINKGO BIOWORKS HOLDINGS, INC. Date: August 29, 2025 By: /s/ Karen Tepichin Name: Karen Tepichin Title: General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR